Ali Hosni Abdalaty is currently an assistant professor at University of Toronto Department of Radiation Oncology and radiation oncologist clinician-investigator at the Radiation Medicine Program - Princess Margaret Cancer Centre, and Clinician-Scientist of the Ontario Association of Radiation Oncologists. My research focus relates to my MSc and PhD work, and is aligned with my training and clinical expertise in head and neck cancer and gastrointestinal malignancies. I have global interest in clinical and experimental radiobiology with specific focus on the radiobiological principles that derive the tumour response and treatment-related toxicity. The overarching goal of my academic career and creative professional activity (CPA) is to improve the value of cancer care through developing optimal radiation therapeutic approach, implementing technology-driven research for radiation therapy innovation that contributes to clinical improvement, building and validation of outcome prediction models, and uncovering novel biomarkers that can be the basis of future clinical trials evaluating tailored new treatment de-escalation or intensification strategies.

Jonathan Loree is a GI medical oncologist at BC Cancer and Assistant Professor at the University of British Columbia. He completed medical school and internal medicine at the University of Alberta before moving to British Columbia for his medical oncology fellowship. He then undertook a translational research fellowship at MD Anderson Cancer Center before returning to work on staff at BC Cancer. He is the CCTG Colon Cancer Disease Site Co-chair, a member of the IND Executive Committee, leads the BC Cancer GI Clinical Trials Unit and his research focus is biomarker development in colorectal cancer and neuroendocrine neoplasms.

Dr. Prica is a staff hematologist at Princess Margaret Cancer Centre and assistant professor in the division of hematology at University of Toronto. She is currently the site lead of the lymphoma and myeloma program at Princess Margaret Cancer Centre. She did her initial medical training in Toronto and her clinical training in Internal Medicine and Hematology in the University of Toronto Program. She completed a 2- year fellowship in Malignant Hematology at the Sunnybrook Health Sciences Centre and a Masters in Health Research Methodology at McMaster University with research interests in quality of life and economic evaluations. Her clinical work focuses in both lymphoproliferative and plasma cell disorders, as well as autologous stem cell transplantation and CAR-T therapy. Her research interests focus on health services research, particularly economic evaluations, and decision analyses for oncologic questions examining resource use and cost of care, as well as toxicity of chemotherapies and their effects on quality of life and caregiver burden. She is a member of the Committee for Economic Analysis and the Quality of Life Committee within the CCTG, as well as the Hematology Disease Site Group.

Dr. Renouf is a medical oncologist at BC Cancer Vancouver and an Associate Professor at the University of British Columbia, Department of Medicine. He received his Doctor of Medicine from the University of Alberta and completed his internal medicine and medical oncology training at the University of British Columbia and BC Cancer. He undertook further training in early drug development and gastrointestinal oncology at Princess Margaret Hospital and the University of Toronto and obtained a Masters of Public Health from Harvard University. Dr. Renouf’s research interests include developmental therapeutics, genomics, and biomarker development within gastrointestinal cancers with a focus on pancreatic cancer. He is the leader of the BC Cancer Phase I program, the BC Cancer GI Tumour Group chair, the Co-Director of Pancreas Centre BC and is the Co-chair of CCTG’s Pancreatic Cancer disease group.

Dr. Srinivas Raman completed his medical school at University of British Columbia and his radiation oncology residency at University of Toronto. During his residency, he worked with Dr. Edward Chow and the CCTG Quality of Life Committee to perform secondary analyses on the SC.20 and SC.23 trials. His research validates the use of the EORTC QLQ-BM22 questionnaire in patients with bone metastases and informs the interpretation of score changes in the QLQ-BM22 and QLQ-C15-PAL/QLQ-C30 instruments. He won the Multinational Association of Supportive Care in Cancer 2016 Young Investigator Award for these research efforts. He is currently a radiation oncology fellow at BC Cancer Vancouver. He is working with Dr. Alan Nichol, the HN6 trial team and the CCTG Quality Assurance committee to develop methodology to individualize and automate radiotherapy quality assurance in clinical trials; he received the 2018 Canadian Association of Radiation Oncology fellowship award for this research proposal. His clinical sites of interest include central nervous system, lung and genitourinary malignancies. His research efforts are currently focused on radiotherapy quality assurance and machine learning applications in oncology.

Dr. Fairchild graduated with a Bachelor of Science from McGill University in Montreal and obtained her MD from Queen’s University in Kingston. She began residency in radiation oncology at the Tom Baker Cancer Centre in Calgary and completed her training at the Cross Cancer Institute in Edmonton. After receiving FRCPC certification in 2006 and completing a one-year clinical / research fellowship at the Cross, she received her first faculty appointment at the University of Alberta in 2007. She took a sabbatical from practice to complete an additional fellowship year in Brussels, as the first North American EORTC Fellow in Quality Assurance in Radiation Oncology. She is currently Associate Professor at the University of Alberta specializing in treating lung and gastrointestinal malignancies, and is a member of the clinical treatment team of the Advanced Imaging and Gamma Knife Centre, University of Alberta Hospital. Her research is focused in the areas of radiotherapy QA within cooperative group trials, palliative radiation, supportive care, and patient-reported outcomes. She was the Canadian Co-Chair of SC.23, and is a member of CCTG’s Data Safety Monitoring Committee and Radiation Oncology Quality Assurance Committee. She is a trial committee member and local site PI of HE.1.

Dr. Cheung is a medical oncologist and a nationally and internationally recognized cancer health services researcher. From 2010 to 2016, he worked in Vancouver at BC Cancer. In 2017, he was recruited to Alberta, where he is currently an Associate Professor of Medicine in the Department of Oncology at the University of Calgary and the Provincial Director of Health Services Research for Cancer Control Alberta. Dr. Cheung received his medical degree at the University of British Columbia, medical oncology subspecialty training at the University of Toronto and subsequently obtained a Master of Public Health degree at Harvard University. He is a prior Chair of the ASCO Health Services Research Scientific Program Committee. Having published over 120 peer-reviewed scientific manuscripts, he is the recipient of numerous accolades for his real-world studies in oncology and has secured over $5 million in research grant funding as a Principal Investigator. He continues to contribute to the Canadian Cancer Trials Group by serving on its Economic Analysis Committee and Quality of Life Committee.

Dr. Skamene is a medical oncology fellow at McGill University. She completed her MD (in 2010), internal medicine and hematology training (in 2015) at McGill University, followed by a 12-month clinical trials fellowship focusing on the design and conduct of phase II/III clinical trials at the Canadian Cancer Trials Group. During her fellowship, she completed a secondary analysis of the LY.12 randomized clinical trial evaluating outcomes of patients with peripheral T-cell lymphoma, which has been accepted for publication in Leukemia & Lymphoma. In addition, she received the John H. Crookston award by the Canadian Hematology Society and an American Society of Hematology Abstract achievement award in 2016 for her project on wait times for autologous stem cell transplantation in relapsed or refractory lymphoma. Her clinical area of interest is in hematologic malignancies and geriatric oncology.

Dr. Tang is a medical oncologist at the Tom Baker Cancer Centre. She completed her MD with Distinction and Honors in Research at the University of Alberta, oncology training at the University of Calgary, followed by an 18-month drug development fellowship focusing on design of early phase clinical trials and biomarker development at the Princess Margaret Cancer Centre, University of Toronto. She was awarded an ASCO Young Investigator Award in 2007. Currently, she is the Southern Alberta Gastrointestinal Tumor Group Leader, the Alberta Representative to 3CTN, as well as the Centre Representative for the

Dr. Cheung obtained his Medical Degree (1999) and also completed residency programs in Internal Medicine and Hematology (1999-2004) at the University of Toronto. In 2006, he obtained a Masters degree in Clinical Epidemiology at the Harvard School of Public Health in Boston. Dr. Cheung is currently on staff at Sunnybrook Health Sciences Centre as a Clinician-Investigator and Clinical Hematologist. He is an Assistant Professor in the Department of Medicine at the University of Toronto. He serves on the Hematology Disease Site Executive Committee for the Canadian Cancer Trials Group, the Committee for Economic Analysis, and is Co-Chair of the Hematology Cancer Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care. His research interests include pharmacoeconomic evaluation in hematologic malignancies, clinical trials in lymphoma and AIDS-related malignancies.